News ArchivesRead News
Synergistic Interaction Enhances Pathogenesis of Parkinson's Disease
Thursday December 24, 2009
Science Daily - Scientists have identified a synergistic interaction that disrupts normal intracellular transport mechanisms and leads to the accumulation of neuron-damaging clumps of protein associated with Parkinson's disease (PD), a neurodegenerative disorder that is characterized by a specific loss of neurons in the midbrain and brainstem. The research, published by Cell Press in the December 24 issue of the journal Neuron, identifies a new potential therapeutic option for preventing PD-associated neuropathology.
Mutations in the alpha--synuclein (α-syn) and Leucine-rich repeat kinase (LRRK2) genes have been linked with inherited and sporadic forms of PD and previous research has shown that accumulation of cytotoxic α-syn protein inside of neurons represents a key step in the pathogenesis of PD. "Although earlier studies have suggested interplay between α-syn and LRRK2, a synergistic interaction in the pathogenesis of PD has not been established," explains senior study author Dr. Huaibin Cai from the Laboratory of Neurogenetics at the National Institutes of Health in Bethesda, Maryland.
In order to systematically investigate whether LRRK2 and α-syn act synergistically to potentiate PD, Dr. Cai and colleagues generated and characterized several types of transgenic mice that overexpressed different combinations of a PD-related alpha-syn mutation along with various forms of normal and PD-associated LRRK2. The researchers found that although overexpression of LRRK2 alone did not cause neurodegeneration, excess LRRK2 significantly accelerated the progression of neuropathological abnormalities in transgenic mice expressing PD-related α-syn.
Overexpression of LRRK2 disrupted key structures and mechanism that play a role in transporting proteins inside of the neurons. Importantly, genetic disruption of LRRK2 maintained normal intracellular transport and reduced the accumulation of α-syn, thereby significantly delaying the progression of PD pathology in the PD α-syn transgenic mice. These findings suggest that LRRK2 exacerbates the abnormal intracellular accumulation of α-syn.
"We have uncovered a novel function for LRRK2 in regulating the intracellular trafficking and accumulation of α-syn in neurons and our results suggest that excessive amounts of LRRK2 or its mutants may result in abnormal neuron-damaging accumulation of α-syn protein," concludes Dr. Cai. "It is possible that inhibition of LRRK2 expression may provide an applicable therapeutic strategy to ameliorate α-syn-induced neurodegeneration in PD or other related neurodegenerative diseases."
Recent NewsOct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 18 - Fighting Parkinson's disease through dance
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show